Abstract:Background and objective: The major causes of mortality among patients who survive acute lung injury/ARDS (ALI/ARDS) are due to the extensive tissue remodelling and fibrosis. Use of high-dose glucocorticoids to reduce these inflammatory and fibroproliferative responses has been shown to do more harm than good. Recently, Meduri et al. found that the early use of low-dose prolonged methylprednisolone in patients with severe ALI/ARDS significantly relieved the systemic inflammatory response and improved pulmonary and extrapulmonary organ function. This study investigated the therapeutic effect of low-dose dexamethasone (Dex) on inflammation and fibrosis in LPS-induced ALI in rats and its influence on the expression of the pulmonary glucocorticoid receptor (GR).Methods: Eighty Wistar rats were randomly divided into four groups: a control group (intraperitoneal normal saline injection (5 mL/kg) throughout experiment, n = 24); the LPS model group (LPS injection (5 mg/kg) for 3 days and normal saline thereafter, n = 24); the LPS + Dex group (LPS injection for 3 days and Dex solution (5 mg/kg) thereafter, n = 16); and the Dex group (normal saline injection (5 mL/kg) for 3 days and Dex solution (5 mg/kg) thereafter, n = 16). Levels of tumor necrosis factor-alpha, matrix metallopeptidase-9 and procollagen N-terminal propeptide type I in BAL fluid were examined by ELISA on the third, seventh and fourteenth days after injection. Pulmonary hydroxyproline content was measured and histological examination was performed with haematoxylin-eosin and Victoria blue-ponceau. Pulmonary distribution of GR-positive cells was examined immunohistochemically, and expression of GR mRNA and protein was determined by RT-PCR and western blot analysis.Results: Histological assessments showed that pulmonary fibrosis occurred in parallel with inflammation in the rat ALI model. Compared with the LPS group, the inflammation and fibrosis parameters were significantly improved in the LPS + Dex group at different periods after injection (P < 0.05 or P < 0.01), although parameters in the LPS + Dex group were not as good as those of the control group. GR mRNA and protein expression in the LPS + Dex group were markedly higher than that of the LPS group on the seventh and the fourteenth days (both P < 0.01). Western blotting showed that Dex also promoted the nuclear translocation of GR protein.Conclusion: Low-dose Dex can reduce pulmonary inflammation and fibrosis after LPS-induced ALI in rats and can elevate GR expression in the lung, probably through upregulating GR levels and promoting the nuclear translocation of GR protein.

Dexmedetomidine Ameliorates LPS Induced Acute Lung Injury Via GSK-3β/STAT3-NF-κB Signaling Pathway in Rats

The Protective Effect of Dexmedetomidine on LPS-induced Acute Lung Injury Through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR Pathways

The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways.

Dexmedetomidine Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury In Rats By Inhibiting Inflammation And Oxidative Stress Via The Gsk-3 Beta/Nrf2 Signaling Pathway

Dexmedetomidine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting the PI3K/Akt/FoxO1 signaling pathway

Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats.

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Liver Oxidative Stress and Cell Apoptosis in Rats by Increasing GSK-3β/MKP-1/Nrf2 Pathway Activity Via the Α2 Adrenergic Receptor.

Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting the NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-κB pathway.

Dexmedetomidine protects against lipopolysaccharide-induced early acute kidney injury by inhibiting the iNOS/NO signaling pathway in rats.

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Regulation of Microrna-223-3p and HDAC4

Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in Vivo and in Vitro

Dexmedetomidine Alleviates Blunt Chest Trauma and Hemorrhagic Shock‑resuscitation‑induced Acute Lung Injury Through Inhibiting the NLRP3 Inflammasome.

Effect of Dexmedetomidine on JAK2/STAT3 Signaling Pathway in Mice with Endotoxin-Induced Acute Lung Injury

Dexmedetomidine Enhances Autophagy via α2-AR/AMPK/mTOR Pathway to Inhibit the Activation of NLRP3 Inflammasome and Subsequently Alleviates Lipopolysaccharide-Induced Acute Kidney Injury.

Effects of Dexmedetomidine on NLRP3 Inflammasome During Acute Lung Injury Induced by Blunt Chest Trauma and Hemorrhagic Shock-Resuscitation in Rats

Low-Dose Dexamethasone Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Rats and Upregulates Pulmonary Glucocorticoid Receptors

Dexmedetomidine Protects Against Lipopolysaccharide-Induced Acute Kidney Injury by Enhancing Autophagy Through Inhibition of the PI3K/AKT/mTOR Pathway

Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway

Dexmedetomidine Enhances Autophagy <i>via</i> 2-AR/AMPK/mTOR Pathway to Inhibit the Activation of NLRP3 Inflammasome and Subsequently Alleviates Lipopolysaccharide-Induced Acute Kidney Injury

Effect of Dexmedetomidine on Kidney Injury in Sepsis Rats Through TLR4/MyD88/NF-κB/iNOS Signaling Pathway.

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Sympathetic Activation and Sepsis via Suppressing Superoxide Signaling in Paraventricular Nucleus